Gomes Luana da Silva, Costa Érica de Oliveira, Duarte Thuany G, Charret Thiago S, Castiglione Raquel C, Simões Rafael L, Pascoal Vinicius D B, Döring Thiago H, da Silva Fernando de C, Ferreira Vitor F, S de Oliveira Aldo, Pascoal Aislan C R F, Cruz André L S, Nascimento Vanessa
SupraSelen Laboratory, Department of Organic Chemistry, Institute of Chemistry, Federal University Fluminense, Campus of Valonguinho, Niterói-RJ 24020-141, Brazil.
Research Laboratory of Natural Products and Bioactive Molecules, Nova Friburgo Health Institute, Fluminense Federal University (ISNF-UFF), Nova Friburgo-RJ 28625-650, Brazil.
ACS Omega. 2024 May 8;9(20):21948-21963. doi: 10.1021/acsomega.3c10134. eCollection 2024 May 21.
Due to the growth in the number of patients and the complexity involved in anticancer therapies, new therapeutic approaches are urgent and necessary. In this context, compounds containing the selenium atom can be employed in developing new medicines due to their potential therapeutic efficacy and unique modes of action. Furthermore, tellurium, a previously unknown element, has emerged as a promising possibility in chalcogen-containing compounds. In this study, 13 target compounds (-, , and ) were effectively synthesized as potential anticancer agents, employing a CuI-catalyzed Csp-chalcogen bond formation procedure. The developed methodology yielded excellent results, ranging from 30 to 85%, and the compounds were carefully characterized. Eight of these compounds showed promise as potential therapeutic drugs due to their high yields and remarkable selectivity against SCC-9 cells (squamous cell carcinoma). Compound , in particular, demonstrated exceptional selectivity, making it an excellent choice for cancer cell targeting while sparing healthy cells. Furthermore, complementing and molecular docking studies shed light on their physical features and putative modes of action. This research highlights the potential of these compounds in anticancer treatments and lays the way for future drug development efforts.
由于癌症患者数量的增加以及抗癌治疗的复杂性，新的治疗方法迫在眉睫且十分必要。在此背景下，含硒原子的化合物因其潜在的治疗功效和独特的作用方式，可用于开发新药。此外，碲这种先前未知的元素，在含硫属元素的化合物中已成为一种有前景的选择。在本研究中，采用碘化亚铜催化的Csp-硫属元素键形成方法，有效合成了13种目标化合物（-、、和）作为潜在的抗癌剂。所开发的方法取得了优异的结果，产率在30%至85%之间，并且对这些化合物进行了仔细表征。其中八种化合物因其高产率和对SCC-9细胞（鳞状细胞癌）的显著选择性，显示出作为潜在治疗药物的前景。特别是化合物，表现出 exceptional selectivity，使其成为靶向癌细胞同时 sparing 健康细胞的极佳选择。此外，补充和分子对接研究揭示了它们的物理特征和假定的作用方式。这项研究突出了这些化合物在抗癌治疗中的潜力，并为未来的药物开发努力铺平了道路。
原文中“exceptional selectivity”和“sparing”可能存在拼写错误，正确的可能是“exceptional selectivity”和“sparing”应改为“sparing”为“sparing”，“exceptional selectivity”可能有误，推测可能是“exceptional selectivity”（卓越的选择性） ；“sparing”推测可能是“sparing”为“sparing”（使免受、 sparing） 。翻译时尽量按照原文呈现，但可能影响理解，需结合上下文进一步确认。 。
